Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

324 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of BRCA1-like triple-negative breast cancers by quantitative multiplex-ligation-dependent probe amplification (MLPA) analysis of BRCA1-associated chromosomal regions: a validation study.
Gross E, van Tinteren H, Li Z, Raab S, Meul C, Avril S, Laddach N, Aubele M, Propping C, Gkazepis A, Schmitt M, Meindl A, Nederlof PM, Kiechle M, Lips EH. Gross E, et al. Among authors: van tinteren h. BMC Cancer. 2016 Oct 19;16(1):811. doi: 10.1186/s12885-016-2848-2. BMC Cancer. 2016. PMID: 27756336 Free PMC article.
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, de Vries EG, Rodenhuis S, van de Vijver MJ. Hannemann J, et al. Among authors: van hoesel qg, van der wall e, van de vijver mj, van tinteren h. Br J Cancer. 2006 Nov 20;95(10):1334-41. doi: 10.1038/sj.bjc.6603449. Epub 2006 Oct 31. Br J Cancer. 2006. PMID: 17088909 Free PMC article. Clinical Trial.
Differential diagnosis of pulmonary carcinoma following head and neck cancer by genetic analysis.
Geurts TW, van Velthuysen ML, Broekman F, van Huysduynen TH, van den Brekel MW, van Zandwijk N, van Tinteren H, Nederlof P, Balm AJ, Brakenhoff RH. Geurts TW, et al. Among authors: van huysduynen th, van den brekel mw, van velthuysen ml, van tinteren h, van zandwijk n. Clin Cancer Res. 2009 Feb 1;15(3):980-5. doi: 10.1158/1078-0432.CCR-08-1968. Clin Cancer Res. 2009. PMID: 19188169
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
Vollebergh MA, Lips EH, Nederlof PM, Wessels LFA, Schmidt MK, van Beers EH, Cornelissen S, Holtkamp M, Froklage FE, de Vries EGE, Schrama JG, Wesseling J, van de Vijver MJ, van Tinteren H, de Bruin M, Hauptmann M, Rodenhuis S, Linn SC. Vollebergh MA, et al. Among authors: van de vijver mj, van beers eh, van tinteren h. Ann Oncol. 2011 Jul;22(7):1561-1570. doi: 10.1093/annonc/mdq624. Epub 2010 Dec 6. Ann Oncol. 2011. PMID: 21135055 Free PMC article. Clinical Trial.
A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study.
Drukker CA, Bueno-de-Mesquita JM, Retèl VP, van Harten WH, van Tinteren H, Wesseling J, Roumen RM, Knauer M, van 't Veer LJ, Sonke GS, Rutgers EJ, van de Vijver MJ, Linn SC. Drukker CA, et al. Among authors: van harten wh, van t veer lj, van de vijver mj, van tinteren h. Int J Cancer. 2013 Aug 15;133(4):929-36. doi: 10.1002/ijc.28082. Epub 2013 Mar 4. Int J Cancer. 2013. PMID: 23371464 Free PMC article.
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients.
Baird RD, van Rossum AGJ, Oliveira M, Beelen K, Gao M, Schrier M, Mandjes IAM, Garcia-Corbacho J, Vallier AL, Dougall G, van Werkhoven E, Linossi C, Kumar S, van Tinteren H, Callari M, Beddowes E, Perez-Garcia JM, Rosing H, Platte E, Nederlof P, Schot M, de Vries Schultink A, Bernards R, Saura C, Gallagher W, Cortès J, Caldas C, Linn SC. Baird RD, et al. Among authors: van rossum agj, van werkhoven e, van tinteren h. Clin Cancer Res. 2019 Nov 15;25(22):6598-6605. doi: 10.1158/1078-0432.CCR-19-0508. Epub 2019 Aug 22. Clin Cancer Res. 2019. PMID: 31439579 Clinical Trial.
Tumour-infiltrating lymphocytes (TILs) and BRCA-like status in stage III breast cancer patients randomised to adjuvant intensified platinum-based chemotherapy versus conventional chemotherapy.
de Boo L, Cimino-Mathews A, Lubeck Y, Daletzakis A, Opdam M, Sanders J, Hooijberg E, van Rossum A, Loncova Z, Rieder D, Trajanoski Z, Vollebergh M, Sobral-Leite M, van de Vijver K, Broeks A, van der Wiel R, van Tinteren H, Linn S, Horlings HM, Kok M. de Boo L, et al. Among authors: van der wiel r, van rossum a, van de vijver k, van tinteren h. Eur J Cancer. 2020 Mar;127:240-250. doi: 10.1016/j.ejca.2019.12.003. Epub 2020 Jan 16. Eur J Cancer. 2020. PMID: 31956037 Clinical Trial.
Carboplatin-Cyclophosphamide or Paclitaxel without or with Bevacizumab as First-Line Treatment for Metastatic Triple-Negative Breast Cancer (BOOG 2013-01).
van Rossum AGJ, Mandjes IAM, van Werkhoven E, van Tinteren H, van Leeuwen-Stok AE, Nederlof P, Portielje JEA, van Alphen RJ, Platte E, van den Broek D, Huitema A, Kok M, Linn SC, Oosterkamp HM. van Rossum AGJ, et al. Among authors: van werkhoven e, van alphen rj, van den broek d, van tinteren h, van leeuwen stok ae. Breast Care (Basel). 2021 Dec;16(6):598-606. doi: 10.1159/000512200. Epub 2021 Jan 22. Breast Care (Basel). 2021. PMID: 35087363 Free PMC article.
324 results